GlassScriptPhysician profile
John M Wegner
NPI 1003892696
$456.19
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $222 · 2024: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $87.52 | 2023-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $84.23 | 2023-2024 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $57.21 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $41.54 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $35.99 | 2024 | Repatha, Otezla |
| Lilly USA, LLC | $33.73 | 2024 | Mounjaro, Zepbound |
| Edwards Lifesciences Corporation | $27.27 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $23.98 | 2023 | Rotateq, Vaxelis, Vaxneuvance |
| Pfizer INC. | $19.52 | 2024 | |
| Exact Sciences Corporation | $16.23 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.66 | 2023 | |
| Mylan Specialty L.P. | $14.31 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wegner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.